Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome
DOI: https://doi.org/10.2147/DMSO.S362424
2022-04-24
Abstract:Dongxu Wang, 1 Bing He 2 1 Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China; 2 Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China Correspondence: Bing He, Department of Endocrinology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang, 110004, People's Republic of China, Tel/Fax +86-24-96615-23111, Email Polycystic ovary syndrome (PCOS) is one of the most common reproductive, endocrine, and metabolic disorders in premenopausal women. Clinically, PCOS is mainly caused by androgen excess and ovarian dysfunction, manifested by anovulatory menstrual cycles, infertility, and hirsutism. In addition, PCOS increases the risk of insulin resistance, obesity, cardiovascular disease, anxiety and depression, dyslipidemia, and endometrial cancer. Nonalcoholic fatty liver disease (NAFLD) is defined as ≥ 5% fat accumulation in the liver in the absence of remaining secondary causes and has become one of the most common chronic liver diseases worldwide. The prevalence of NAFLD is significantly higher and more severe in women with PCOS, and its pathogenesis can be associated with various risk factors such as hyperandrogenemia, insulin resistance, obesity, chronic low-grade inflammation, and genetic factors. Although there is no definitive solution for the management of NAFLD in PCOS, some progress has been made. Lifestyle modification should be the basis of management, and drugs to improve metabolism, such as insulin sensitizers and glucagon-like peptide-1 agonists, may show better efficacy. Bariatric surgery may also be a treatment of NAFLD in obese women with PCOS. This paper reviews three aspects of prevalence, risk factors, and management, in order to better understand the current state of research on NAFLD in PCOS, to explore the pathogenesis of NAFLD in PCOS, and to encourage further research on the application of drugs in this field. Keywords: polycystic ovary syndrome, nonalcoholic fatty liver disease, hyperandrogenemia, insulin resistance, obesity, metformin, glucagon-like peptide-1 Polycystic ovary syndrome (PCOS) is one of the most common reproductive, endocrine, and metabolic disorders in premenopausal women. 1 PCOS is a group of syndromes caused by excessive androgens and ovarian dysfunction. 2 Diagnostic criteria for PCOS vary internationally and mainly follow the standards proposed by the National Institutes of Health (NIH) of the United States in 1990, 3 the Rotterdam standards proposed by the European Society of Reproductive Medicine and the American Society of Reproductive Medicine in 2003, 4 and the Androgen Excess Society (AES) standard proposed by the American Androgen Hypertrophy Society in 2006, 5 as shown in Table 1. The Rotterdam standard is currently the most widely used, and the worldwide prevalence of PCOS varies somewhat depending on the diagnostic criteria, ranging from 4% to 21%. 6 The clinical manifestations of PCOS are mainly anovulatory menstrual cycles, infertility, and hirsutism. 7 In addition, PCOS increases the risk of insulin resistance, obesity, cardiovascular disease, anxiety and depression, dyslipidemia, and endometrial cancer. 8–12 Table 1 Diagnostic Criteria for PCOS Nonalcoholic fatty liver disease (NAFLD) is defined as ≥5% fat accumulation in the liver with the absence of remaining secondary causes, such as viral hepatitis, excessive alcohol consumption, drug-related liver disease, autoimmune liver disease, genetic metabolic liver disease, and other diseases. 13 NAFLD includes a wide range of histological changes from simple fat accumulation in the liver to nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis, and even hepatocellular carcinoma (HCC). 14 With a global prevalence of 25.24%, 15 NAFLD has become one of the most common chronic liver diseases worldwide and may become a major cause of end-stage liver disease in the coming decades. As a result, NAFLD has gained the attention of physicians, experts, and health policy makers worldwide. 16 Recent studies have found a significant increase in the prevalence of NAFLD in PCOS. Therefore, in this review, we will discuss the research progress of NAFLD in PCOS from three aspects: prevalence, risk factors, and management. In 2005, Brown et al 17 reported a 24-year-old patient with PCOS and chronically elevated serum transaminase levels who had a liver biopsy confirming severe NASH. Since then, there has been a gradual increase in clinical studies on NAFLD in PCOS, according to the data reported in the studies, we found that the prevalence range for NAFLD in PCOS was 14.5%–77%,< -Abstract Truncated-